Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Lymphoma Clinical Trial

Official title:

Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00006379
• Other study ID #: CWRU3Y00
• Secondary ID: P30CA043703CWRU-
• Status: Completed
• Phase: Phase 2
• First received: October 4, 2000
• Last updated: December 7, 2011
• Start date: June 2000
• Est. completion date: October 2011

Study information

• Verified date: December 2011
• Source: Case Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells.

PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating patients who have hematologic cancer or aplastic anemia.

Description:

OBJECTIVES:

• Determine the rates of durable full donor hematologic engraftment in patients with high-risk hematologic malignancies or severe aplastic anemia treated with non-myeloablative conditioning using fludarabine, cyclophosphamide, and anti-thymocyte globulin followed by allogeneic peripheral blood stem cell transplantation.

• Determine the acute and delayed toxic effects of this non-myeloablative conditioning regimen in this patient population.

• Determine the event-free and overall survival of patients treated with this regimen.

• Determine the incidence and severity of acute and chronic graft-versus-host disease in patients treated with this regimen.

• Determine the rate and quality of immune reconstitution in patients treated with this regimen.

• Determine the rate of disease relapse and incidence of post-transplantation lymphoproliferative disease in these patients.

OUTLINE: Patients are stratified according to disease category (malignant vs non-malignant) and graft source (unrelated vs HLA-matched sibling).

Beginning at least 4 weeks after conventional-dose chemotherapy, patients receive non-myeloablative conditioning comprising fludarabine IV over 30 minutes on days -8 to -4, cyclophosphamide IV over 2 hours on days -3 to -2, and anti-thymocyte globulin IV over at least 4 hours on days -2 and -1. Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.

Patients are followed weekly for 3 months, every 2 weeks for 3 months, monthly for 6 months, and then every 2 months thereafter.

PROJECTED ACCRUAL: A minimum of 30 patients will be accrued for this study within 4 years.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 58
• Est. completion date: October 2011
• Est. primary completion date: January 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 70 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically proven high-risk hematologic malignancy

• Acute non-lymphocytic leukemia (ANLL) after induction failure, or in first complete remission (CR) with high-risk features, including any of the following:

• Stem cell or biphenotypic classification (AML-M0)

• Erythroleukemia (AML-M6)

• Acute megakaryocytic leukemia (AML-M7)

• Cytogenetic markers indicative of poor prognosis

• Failure to achieve CR after standard induction therapy

• Acute lymphocytic leukemia (ALL) or ANLL in relapse or second or subsequent remission

• Chronic myelogenous leukemia (CML) in chronic or accelerated phase

• Patients with CML in blast crisis are eligible after reinduction chemotherapy places them in chronic phase

• High-risk ALL in first CR with high risk defined by presence of t(4;11), t(9;22) translocation, hyperleukocytosis (initial WBC greater than 30,000/mm^3), or failure to achieve CR by day 28 after standard induction

• No T-cell ALL or t(8;14) positive B-cell ALL in first remission with hyperleukocytosis

• Myelodysplastic syndrome by peripheral blood smear and bone marrow examination

• Refractory to medical management OR

• Cytogenetic abnormalities predictive of transformation into acute leukemia including 5q-, 7q-, monosomy 7, and trisomy 8 OR

• Evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation)

• Multiple myeloma, non-Hodgkin's lymphoma (NHL), ANLL, or ALL with recurrent disease after autologous stem cell transplantation (SCT)

• At least 3 months since prior autologous SCT

• Hodgkin's lymphoma, NHL, or multiple myeloma beyond first CR or primary induction failures whose disease has demonstrated sensitivity to pre-transplantation cytoreduction (defined as greater than 50% reduction in tumor burden)

• Mantle zone NHL allowed after induction therapy

• Myeloproliferative disorder that is non-responsive to medical management and requires allografting, unless evidence of grade 3 or worse myelofibrosis on marrow biopsy OR

• Histologically proven acquired severe aplastic anemia (SAA) that is recurrent or unresponsive after anti-thymocyte globulin and/or cyclosporine

• SAA defined by at least 2 of the following conditions:

• Granulocyte count less than 500/mm^3

• Platelet count less than 20,000/mm^3

• Absolute reticulocyte count less than 20,000/mm^3 after correction for hematocrit

• Ineligible for full ablative conditioning due to any of the following conditions:

• Prior extensive therapy (more than 2 salvage chemotherapy regimens and/or autologous transplantation)

• Over age 55 OR

• Under age 55 with comorbid disease (e.g., suboptimal cardiac, pulmonary, or renal function and/or prior life-threatening infection)

• HLA-A, B, and DR phenotypically identical sibling donor OR

• HLA-A, B, and DR identical genetically matched unrelated donor

• No ANLL in first CR (less than 5% blasts in marrow) with translocations t(8;21) and inv(16) unless failed first-line induction therapy OR

• No ANLL in first CR (less than 5% blasts in marrow) with translocations t(15;17) abnormality unless failed first-line induction therapy OR molecular evidence of persistent disease

• No active CNS disease

PATIENT CHARACTERISTICS:

Age:

• 0 to 70

Performance status:

• Zubrod 0-1

• Karnofsky 80-100%

Life expectancy:

• At least 3 months

Hematopoietic:

• See Disease Characteristics

Hepatic:

• ALT/AST no greater than 4 times normal

• Bilirubin no greater than 2.0 mg/dL

Renal:

• See Disease Characteristics

• Creatinine clearance at least 50 mL/min

Cardiovascular:

• See Disease Characteristics

• Shortening fraction or ejection fraction at least 40% of normal for age by echocardiogram or radionuclide scan

• No clinically significant comorbid illnesses (e.g., myocardial infarction or cerebrovascular accident)

Pulmonary:

• See Disease Characteristics

• FVC and FEV_1 at least 60% of predicted for age

• DLCO at least 60% of predicted for adults

Other:

• No severe neurosensory symptoms (i.e., peripheral neuropathy)

• HIV negative

• Active infection allowed if controlled by appropriate drug therapy

• Not pregnant or nursing

• Negative pregnancy test

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• See Disease Characteristics

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified

Other:

• Recovered from prior therapy

• No concurrent investigational agents unless approved by protocol investigators

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Myeloproliferative Disorders
• Leukemia
• Lymphoma
• Multiple Myeloma
• Multiple Myeloma and Plasma Cell Neoplasm
• Myelodysplastic Syndromes
• Myelodysplastic-Myeloproliferative Diseases
• Myelodysplastic/Myeloproliferative Diseases
• Myeloproliferative Disorders
• Neoplasms, Plasma Cell
• Plasmacytoma
• Precancerous Conditions
• Precancerous/Nonmalignant Condition
• Preleukemia
• Small Intestine Cancer

Intervention

Biological:
• anti-thymocyte globulin
anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
• graft-versus-tumor induction therapy
Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.

Drug:
• cyclophosphamide
cyclophosphamide IV over 2 hours on days -3 to -2
• fludarabine phosphate
fludarabine IV over 30 minutes on days -8 to -4

Procedure:
• peripheral blood stem cell transplantation
Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.

Locations

Country	Name	City	State
United States	Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center	Cleveland	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Case Comprehensive Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of Donor Engraftment	Peripheral blood from the donor and patient is obtained for chimerism studies. The primary analysis will consist of estimating the graft failure proportions for each of the separate patient groups and calculating confidence intervals for these proportions. This analysis will be done conditional on patients surviving at least 28 days.	at 28 days	No
Secondary	Stable donor hematopoietic chimerism	Number of Patients Transplanted More Than 100 Days Ago	at day 100	No
Secondary	Event free and overall survival		to progression/death	No